Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

AI helps reduce costs and improve efficiency in drug development. The "AI+Medical" Industry has explosive growth opportunities.

China Post Securities pointed out that the Global market size for AI+Medical industry AI solutions is expected to increase from 13.7 billion dollars in 2022 to 155.3 billion dollars in 2030, with a CAGR of 35.5%, indicating explosive growth opportunities in the industry.

cls.cnFeb 27 19:05 ET

Will pay over 30 million equity dispute amounts. Getein Biotech, Inc has issued multiple lawsuit announcements in the past four months | Brief announcement.

① Getein Biotech, Inc and nine minority shareholders of Jingchuan Diagnostics, including Wuhan Boruihong, have received a final judgment in their equity acquisition dispute. ② According to the judgment, Getein Biotech, Inc will pay over 30 million yuan for the acquisition.

cls.cnFeb 26 09:28 ET

To extend its Industry Chain layout, Sansure Biotech Inc. intends to acquire 54% equity in Hong'an Jiyuan, which has not yet turned a profit.

①Sansure Biotech Inc. stated that the company values the product's ease of operation, good stability, and high cost performance of Hong'an Jiyuan, making it suitable for projects in grassroots Medical Institutions; ②Since the launch of related products from Hong'an Jiyuan in 2024, thousands of blood analyzers have been installed in various provinces across the country within one year.

cls.cnFeb 25 22:29 ET

It was reported that FOSUN PHARMA will sell its Indian pharmaceutical company, and it stated that it will continue to promote the development of the Indian company in the Global market.

① It is rumored that FOSUN PHARMA will sell its pharmaceutical company Gland Pharma located in India, and the company stated it will continue to promote Gland Pharma's development and growth in the Global market. ② Previously, FOSUN PHARMA had reduced its Shareholding in Gland Pharma to supplement working capital, repay interest-bearing debts, and so on.

cls.cnFeb 20 18:46 ET

Huawei will release AI pathology models, and the Medical Industry is迎来 an important opportunity for intelligent upgrades.

① Huawei's data storage public account released information stating that it will launch the Ruijin pathological model based on the Huawei DCS AI solution. ② Jianghai Securities pointed out that under the guidance of the Health China 2030 Global Strategy, the Medical Industry is ushering in an important opportunity for intelligent upgrades.

cls.cnFeb 13 19:04 ET